Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. Dezember 2025 15:10 ET | Quelle: Boehringer Ingelheim Limited

U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults

Not intended for UK audiences Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2Affecting up to 100,000...
19. Dezember 2025 08:20 ET | Quelle: Polyrizon Ltd.

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

The PL-16 Viral Blocker has shown over 90% success in protection of cells against viruses Raanana, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd., a pre-clinical-stage biotechnology...
18. Dezember 2025 14:20 ET | Quelle: Foundation for Sarcoidosis Research

Foundation for Sarcoidosis Research Publishes Comprehensive Voice of the Patient Report Following Externally Led PFDD Meeting with the FDA

The FSR Voice of the Patient report outlines a clear path forward for drug developers, researchers, clinicians, and regulators for sarcoidosis.
18. Dezember 2025 08:05 ET | Quelle: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Sangamo announces it has begun a rolling submission of its BLA to the FDA for , an investigational gene therapy for adults with Fabry disease
18. Dezember 2025 08:00 ET | Quelle: Nutriband Inc.

Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration

Quanta LOI
18. Dezember 2025 07:00 ET | Quelle: Nutriband Inc.

Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction

Fentanyl designation Response
16. Dezember 2025 12:18 ET | Quelle: Equity Insider

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic...
16. Dezember 2025 08:45 ET | Quelle: Clearmind Medicine Inc.

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and...
15. Dezember 2025 08:30 ET | Quelle: NetraMark Holdings Inc.

NetraMark Achieves Major FDA Milestone

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is...
12. Dezember 2025 10:31 ET | Quelle: Equity Insider

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA approved the first perioperative immunotherapy for early gastric and gastroesophageal...

Nächste Seite